Key Takeaways The Food and Drug Administration (FDA) is moving forward with its newest safety review of Mifepristone as an October court deadline approaches in ongoing litigation that could influence the future of telehealth-based medication abortion access nationwide. The review follows recent legal developments, including a Supreme Court order preserving access to mifepristone by mail […]
Key Takeaways The Food and Drug Administration (FDA) is moving forward with its newest safety review of Mifepristone as an October court deadline approaches in ongoing litigation that could influence the future of telehealth-based medication abortion access nationwide. The review follows recent legal developments, including a Supreme Court order preserving access to mifepristone by mail […]
